Sun Pharma Clarifies on 12 Billion USD Organon Acquisition Reports; Share Price Flat; What Pharma Giant Said

Sun Pharmaceutical Industries Limited, one of India's largest pharmaceutical companies has issued a clarification regarding recent market speculation around a potential acquisition of Organon, stating that no such development has been formally confirmed at this stage.

Sun Pharma Plans 12 Billion USD Organon Acquisition? Know Pharma Giant's Official Clarification

In a formal communication dated April 10, 2026, Sun Pharma responded to queries raised by both Bombay Stock Exchange (BSE) Limited and the National Stock Exchange (NSE). The clarification was issued by Anoop Deshpande, Company Secretary and Compliance Officer, addressing reports and discussions in the market about a possible large-scale acquisition.

Sun Pharma Dismisses Deal Reports as Non-Material Under Regulation 30

Sun Pharma emphasised that the information currently circulating is speculative in nature and does not qualify as a material event requiring disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR). The company clearly stated that it has not confirmed any such acquisition at present.

"In this regard, we wish to clarify that the information set out in the article is speculative in nature and there is no material event/ information that requires disclosure under Regulation 30 of the Listing Regulations.....We adhere to the highest standards of governance and disclosures and will keep the stock exchanges informed of any material events as required under Regulation 30 of the Listing Regulations," the company stated in its regulatory filing.

The clarification follows widespread market chatter suggesting that the company could be exploring a significant acquisition opportunity involving Organon, with possible financial backing from global institutions. However, Sun Pharma's response indicates that no definitive agreement or actionable development has been finalised so far.

Sun Pharma Share Price Today

After the clarification, shares of Sun Pharmaceutical Industries Ltd were trading at Rs 1,657.90 on the NSE as of 12:00 pm on April 13, 2026, registering a marginal gain of 0.18%, or Rs 3.00, during the session.

The stock opened at Rs 1,654.90 and moved within a day's range of Rs 1,640.10 on the lower side and Rs 1,668.70 on the higher side.

Know About Organon

Organon, headquartered in the United States (US), was spun off from Merck Sharp & Dohme in 2021 as an independent entity with a strategic focus on women's health, biosimilars and established medicines. The company has since built a diversified portfolio that extends beyond its core women's health segment to include therapies across cardiovascular, respiratory and dermatological conditions, as well as treatments for bone health disorders and non-opioid pain management.

Meanwhile Sun Pharma, led by founder Dilip Shanghvi, continues to maintain a robust balance sheet, supported by healthy net cash reserves that provide flexibility for potential large-scale acquisitions. For FY26, the company reported revenues of approximately Rs 52,000 crore, driven by strong contributions from both its domestic operations in India and its key US market.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.